Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Cited In for PubMed (Select 15557326)

1.

ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.

Leccia F, Del Vecchio L, Mariotti E, Di Noto R, Morel AP, Puisieux A, Salvatore F, Ansieau S.

Mol Cancer. 2014 Sep 12;13:213. doi: 10.1186/1476-4598-13-213.

2.

ABCG2 is a selectable marker for enhanced multilineage differentiation potential in periodontal ligament stem cells.

Szepesi Á, Matula Z, Szigeti A, Várady G, Szabó G, Uher F, Sarkadi B, Német K.

Stem Cells Dev. 2015 Jan 15;24(2):244-52. doi: 10.1089/scd.2014.0177.

PMID:
25101689
3.

Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.

Kapoor K, Bhatnagar J, Chufan EE, Ambudkar SV.

J Biol Chem. 2013 Nov 8;288(45):32622-36. doi: 10.1074/jbc.M113.498980. Epub 2013 Sep 24.

4.

Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.

To KK, Tomlinson B.

Br J Pharmacol. 2013 Nov;170(5):1137-51. doi: 10.1111/bph.12367.

5.

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, Chen ZS, Ambudkar SV, Baer MR.

Mol Cancer Ther. 2012 Sep;11(9):2033-44. doi: 10.1158/1535-7163.MCT-12-0302. Epub 2012 Jul 9.

6.

Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.

Shukla S, Schwartz C, Kapoor K, Kouanda A, Ambudkar SV.

Drug Metab Dispos. 2012 Feb;40(2):304-12. doi: 10.1124/dmd.111.042721. Epub 2011 Oct 31.

7.

Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.

Ni Z, Bikadi Z, Shuster DL, Zhao C, Rosenberg MF, Mao Q.

Biochemistry. 2011 Sep 20;50(37):8057-66. doi: 10.1021/bi200573t. Epub 2011 Aug 26.

8.

Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

Peng H, Qi J, Dong Z, Zhang JT.

PLoS One. 2010 Dec 7;5(12):e15276. doi: 10.1371/journal.pone.0015276.

9.

Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Ni Z, Bikadi Z, Rosenberg MF, Mao Q.

Curr Drug Metab. 2010 Sep;11(7):603-17. Review.

10.

Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.

Ni Z, Bikadi Z, Cai X, Rosenberg MF, Mao Q.

Am J Physiol Cell Physiol. 2010 Nov;299(5):C1100-9. doi: 10.1152/ajpcell.00160.2010. Epub 2010 Aug 25.

11.

Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Sauna ZE, Okunji C, Hunt RC, Gupta T, Allen CE, Plum E, Blaisdell A, Grigoryan V, Geetha S, Fathke R, Soejima K, Kimchi-Sarfaty C.

PLoS One. 2009 Aug 5;4(8):e6506. doi: 10.1371/journal.pone.0006506.

12.

A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.

Peng H, Dong Z, Qi J, Yang Y, Liu Y, Li Z, Xu J, Zhang JT.

PLoS One. 2009 May 24;4(5):e5676. doi: 10.1371/journal.pone.0005676.

13.

Arginine 383 is a crucial residue in ABCG2 biogenesis.

Polgar O, Ediriwickrema LS, Robey RW, Sharma A, Hegde RS, Li Y, Xia D, Ward Y, Dean M, Ozvegy-Laczka C, Sarkadi B, Bates SE.

Biochim Biophys Acta. 2009 Jul;1788(7):1434-43. doi: 10.1016/j.bbamem.2009.04.016. Epub 2009 May 3.

14.

Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.

Robey RW, Obrzut T, Shukla S, Polgar O, Macalou S, Bahr JC, Di Pietro A, Ambudkar SV, Bates SE.

Cancer Chemother Pharmacol. 2009 Aug;64(3):575-83. doi: 10.1007/s00280-008-0908-2. Epub 2009 Jan 9.

15.

The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant.

Polgar O, Deeken JF, Ediriwickrema LS, Tamaki A, Steinberg SM, Robey RW, Bates SE.

Mol Cell Biochem. 2009 Feb;322(1-2):63-71. doi: 10.1007/s11010-008-9940-0. Epub 2008 Nov 11.

16.

Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter.

Ozvegy-Laczka C, Laczkó R, Hegedus C, Litman T, Várady G, Goda K, Hegedus T, Dokholyan NV, Sorrentino BP, Váradi A, Sarkadi B.

J Biol Chem. 2008 Sep 19;283(38):26059-70. doi: 10.1074/jbc.M803230200. Epub 2008 Jul 21.

17.

New inhibitors of ABCG2 identified by high-throughput screening.

Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, Dean M, McMahon JB.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3271-8.

18.
19.

Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.

Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, Dean M, Sarkadi B, Bates SE.

Biochemistry. 2006 Apr 25;45(16):5251-60.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk